CPE, Mirae lead $100m Series B for China's JW Therapeutics
JW Therapeutics, a China cancer treatment specialist established by Bristol Myers Squibb-owned Juno Therapeutics and China’s WuXi AppTec, has received $100 million in Series B funding.
The round was led by CPE – formerly CITIC Private Equity – and Mirae Asset. Additional commitments came from Oriza Holdings and CR-CP Life Science Fund, a $300 million life sciences vehicle established...
More on Greater China
Latest News
China 3D printing start-up WeNext raises $55m
Temasek Holdings, Cathay Capital Private Equity, and Haochen Capital have led a $55 million Series B round for WeNext Technology, a China-based 3D printing specialist.
Vision Fund backs Japan sneaker marketplace
SoftBank Vision Fund 2 has made a Series D investment of undisclosed size in Japan’s Soda, operator of sneaker reselling platform Snkr Dunk, at a valuation of JPY38 billion ($336 million).
Chinese language learning platform raises $105m
Singapore’s LingoAce, a Chinese language learning app, has raised $105 million in Series C funding led by Sequoia Capital India. It comes within a year of a $55 million Series B.
CVC backs take-private of Hong Kong-listed Razer
CVC Capital Partners is supporting a proposed founder-led privatization of Hong Kong-listed gaming hardware and software provider Razer that values the business at HK$24.7 billion ($3.17 billion).